Anecortave acetate

Overview

Anecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.

Indication

Investigated for use/treatment in glaucoma and macular degeneration.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Anecortave Acetate Injection to Treat Steroid-responsive Intraocular Pressure Increase in Cornea Transplant Patients	2009/04/20	NCT00884039	Not Applicable	Terminated	Cornea Research Foundation of America
A Multi-Dose Study With a Treatment for Open-Angle Glaucoma	2008/06/26	NCT00705770	Phase 2	Withdrawn	Alcon Research
Prophylactic Anecortave Acetate in Patients With a Retisert Implant	2007/12/11	NCT00570479	Phase 1	Completed	Texas Retina Associates
Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate	2007/06/21	NCT00489840	Phase 1	Completed	Manhattan Eye, Ear & Throat Hospital
Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate	2006/07/10	NCT00349739	N/A	NO_LONGER_AVAILABLE	University of Iowa
Anecortave Acetate Versus Placebo in AMD Patients Following PDT	2006/06/30	NCT00346866	Phase 2	Completed	Alcon Research
Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)	2005/09/21	NCT00211315	Phase 2	Completed	Manhattan Eye, Ear & Throat Hospital
Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)	2005/09/21	NCT00211354	Phase 2	Withdrawn	Manhattan Eye, Ear & Throat Hospital
Treatment of Idiopathic Perifoveal Telangiectasia (IPT) With Open-Label Anecortave Acetate (15mg.).	2005/09/21	NCT00211328	Phase 2	Completed	Manhattan Eye, Ear & Throat Hospital
Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)	2005/09/21	NCT00211367	Phase 2	Terminated	Manhattan Eye, Ear & Throat Hospital

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access